Dual-Targeting Peptide Conjugates for Cell-Specific CNS Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic agents to the Central Nervous System (CNS) are limited by the blood-brain barrier (BBB), leading to poor biodistribution, off-target effects, and lack of cell specificity, with no general solution available for efficient CNS access.
Innovation Solution
Development of MGS and MTS peptides, which can be conjugated to form dimers or tetramers, allowing targeted delivery to specific cell types in the CNS, such as microglia and neurons, through selective binding and internalization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BBB permeable compounds are used for CNS delivery, then entry into the brain is improved, but biodistribution properties deteriorate and off-target effects increase
Solution Approach 1:
The invention segments the delivery system into two distinct functional components: a BBB-penetrating peptide (e.g., MTS peptide) and a cell-specific targeting peptide (e.g., MGS peptide). This segmentation allows each component to perform its specialized function independently, with the BBB-penetrating component ensuring brain entry and the cell-specific component ensuring precise cellular targeting, thereby avoiding off-target effects while maintaining reliable CNS delivery.
2Reliability
If direct injection into spinal cord or brain is used, then access to CNS is improved, but risk of structural damage and infection increases
Solution Approach 1:
The invention uses peptide conjugates as intermediaries that enable non-invasive CNS delivery. The BBB-penetrating peptide acts as a mediator that facilitates transport across the blood-brain barrier through natural physiological processes, eliminating the need for direct injection and thereby avoiding structural damage and infection risks while maintaining reliable CNS access.
3Reliability
If BBB disruption is used for mass transport, then entry of compounds into CNS is improved, but structural damage and neuronal dysfunction occur
Solution Approach 1:
The invention employs the body's own physiological transport mechanisms for CNS delivery. The BBB-penetrating peptide utilizes natural receptor-mediated transport pathways that the blood-brain barrier already possesses, allowing the system to 'self-service' the transport function without requiring external disruption or damage to the barrier structure, thereby achieving efficient CNS transport while avoiding structural damage.
4Ease of operation
If intranasal delivery is used, then non-invasive administration is improved, but distribution through CNS deteriorates and absorption variability increases
Solution Approach 1:
The invention creates a universal delivery system that can be administered through multiple routes (including intranasal, intravenous, and other non-invasive methods) while maintaining consistent and reliable CNS distribution. The dual-peptide conjugate structure provides multi-functional capability, ensuring that regardless of the administration route, the system achieves predictable brain penetration and cell-specific targeting, thereby eliminating absorption variability while maintaining ease of operation.
5Reliability
If receptor-mediated delivery is used, then transport across BBB is improved, but cell specificity deteriorates and distribution consistency worsens
Solution Approach 1:
The invention merges two previously separate delivery functions into a single conjugate molecule: the BBB-penetrating peptide provides reliable transport across the blood-brain barrier, while the cell-specific targeting peptide provides precise cellular targeting. This merging ensures that both BBB transport and cell specificity are achieved simultaneously in a coordinated manner, eliminating the distribution inconsistency and cell specificity problems that occur when using receptor-mediated delivery alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides enable efficient and specific transport of cargo across the BBB, achieving high cellular uptake and stability in human serum, with potential for therapeutic and imaging applications in CNS disorders.
Implementation Method 1
MTS peptides, which can be conjugated to form dimers or tetramers, allowing targeted delivery to specific cell types in the CNS, such as microglia and neurons, through selective binding and internalization
Implementation Method 2
MGS and MTS peptides, which can be conjugated to form dimers or tetramers, allowing targeted delivery to specific cell types in the CNS, such as microglia and neurons, through selective binding and internalization
Implementation Method 3
allowing targeted delivery to specific cell types in the CNS, such as microglia and neurons, through selective binding and internalization
Data Source
AI summary
Disclosed are MGS peptides, MTS peptides, linkers and combinations combining any combination thereof. Disclosed are MGS peptides comprising the amino acid sequence of any of the sequences set forth in SEQ ID NOs: 1-8 Disclosed are MTS peptides comprising the amino acid sequence of any of the sequences set forth in SEQ ID NOS: 9-14. Disclosed are compositions comprising at least one MGS peptide conjugated to at least one MTS peptide, wherein the MGS peptide comprises the amino acid sequence of GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1); EQRWVQMLHILQTRYAGEWPG (SEQ ID NO: 2); FQHINPFPYTYSMEDTDVEIK (SEQ ID NO: 3); or YAAWPASGAWT (SEQ ID NO: 4). In some aspects, the disclosed compositions can further comprise one or more linkers.